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Copyright © 2009 JCBN Summary The aim of this study was to determine the effects of rice bran oil (RBO) on lipid
metabolism and insulin resistance in rats with streptozotocin/nicotinamide-induced type 2
diabetes mellitus (T2DM). Rats were divided into two groups: the control group (15% soybean
oil, contains 0 g γ-oryzanol and 0 g γ-tocotrienol/150 g oil for 5 weeks) and the RBO group
(15% RBO, contains 5.25 g γ-oryzanol and 0.9 g γ-tocotrienol/150 g oil for 5 weeks). Compared
with the control group, the RBO group had a lower plasma nonesterified fatty acid concen-
tration, ratio of total to high-density-lipoprotein cholesterol, hepatic cholesterol concentration,
and area under the curve for insulin. The RBO group had a higher high-density-lipoprotein
cholesterol concentration and greater excretion of fecal neutral sterols and bile acid than did
the control group. RBO may improve lipid abnormalities, reduce the atherogenic index, and
suppress the hyperinsulinemic response in rats with streptozotocin/nicotinamide-induced
T2DM. In addition, RBO can lead to increased fecal neutral sterol and bile acid excretion.
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Introduction
The prevalence of type 2 diabetes mellitus (T2DM) has
increased greatly in the past few years and a still greater
increase is foreseen in the next few years [1]. For this reason,
T2DM is considered to be one of the epidemics of the new
century. Persons with T2DM have an increased risk of
mortality, primarily because of cardiovascular disease (CVD)
[2, 3]. An important risk factor for the development of CVD
[4] is dyslipidemia, and randomized controlled studies have
shown that a lipid-lowering treatment reduces the risk of
CVD and death [5]. This combination of abnormalities—
elevated blood levels of triglycerides (TGs), low levels of
high-density-lipoprotein cholesterol (HDL-C), and rela-
tively normal levels of low-density-lipoprotein cholesterol
(LDL-C) carried in small, dense, cholesterol-poor LDL
particles—is known as “diabetic dyslipidemia.” Significant
evidence supports a key role for insulin resistance, which
is a central pathophysiologic feature of T2DM in the
development of diabetic dyslipidemia [6].
Many aspects of the diet (carbohydrate, fat, fiber,
vitamins, and alcohol) are considered to be important in the
modulation of insulin resistance; however, in the past few
years, more attention has been given to the ability of the
quality of dietary fat, independent of the total amount, to
influence insulin sensitivity and to increase the risk of
T2DM [7]. Rice bran oil (RBO) is recommended for the
treatment of hyperlipoproteinemia in humans because
plasma total cholesterol (TC), LDL-C, and TG concentra-T.-W. Chou et al.
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tions decrease when this oil is added to the diet [8–10]. A
hypolipidemic response characterized by decreases in serum
concentrations of TG, TC, very-low-density lipoprotein
cholesterol (VLDL-C), and LDL-C has been associated with
feeding RBO to rats [11,  12]. Rice bran also attenuates
hyperglycemia in humans with diabetes mellitus [13].
Soluble components of rice bran lowered fasting glucose
concentrations by 29% and 33%, respectively, in subjects
with type 1 diabetes mellitus and T2DM [13].
In Taiwan, there has been a 5-fold increase in mortality
from DM-related complications in the past 20 years. T2DM
is associated with a high incidence of complications, such as
retinopathies, glomerulopathies, and vascular complications.
However, few studies have investigated the effect of RBO
consumption in the T2DM model. Therefore, the present
study was conducted to determine the effects of RBO
consumption on lipid metabolism and insulin resistance in
rats with streptozotocin (STZ)/nicotinamide-induced T2DM.
Materials and Methods
Animals and diets
Sixteen male Wistar rats aged 6 weeks with a body weight
(BW) of 200 ± 10 g were obtained from the Animal Center
of Taiwan University Medical College, Taipei, Taiwan.
Rats were housed individually in wire-bottomed stainless
steel cages in an air-conditioned room (21 ± 2°C, 50–70%
relative humidity) with a 12-h light-dark cycle and free
access to the basal diet and water for 2 weeks before T2DM
was induced. Diabetes was induced with an intraperitoneal
injection of STZ (45 mg/kg BW), which was followed
15 min later by an injection of nicotinamide (200 mg/kg
BW). After 2 days, this step was repeated using the modified
Masiello method [14]. Nicotinamide and STZ were freshly
prepared in a 0.9% (wt:v) sodium chloride solution. Rats
were considered diabetic when their fasting plasma glucose
concentration was greater than 10 mmol/l 14 days after the
last induction date. At this time, baseline blood samples
were collected from the tail vein of the rats after anesthetiza-
tion with ether gas. Fatty acid composition, areas under the
curve (AUCs) for glucose and insulin, and plasma glucose,
insulin, TG, nonesterified fatty acid (NEFA), and cholesterol
concentrations, were not significantly different from those
of the diabetic rats at baseline. The rats were then fed the
experimental diets.
Diabetic rats were divided into a control or RBO group
(n = 8 per group) and were fed cholesterol-free diets for 5
weeks. The high-fat diets were a modified AIN-93M diet
containing 150 g of fat, 590 g of cornstarch, 200 g of casein,
and 10 g of α-cellulose as fiber/kg diet. Choline, cysteine,
minerals, and vitamins were added as described in AIN-93M
[15]. The experimental diet for the control group contained
15% soybean oil. The experimental diet for the RBO group
contained 15% RBO in place of soybean oil. RBO was
extracted by using the supercritical CO2 fluid extraction
method [16]. Each gram of RBO contained 0.035 g of γ-
oryzanol and 0.006 g of γ-tocotrienol. The 15% RBO diet
contained 5.25 g of γ-oryzanol and 0.9 g of γ-tocotrienol
in 150 g RBO/kg diet (Table 1). All animal experimental
procedures followed published guidelines [17] and were
approved by the Institutional Animal Care and Use
Committee of Taipei Medical University, Taipei, Taiwan.
After consuming the diets for 5 weeks, the diabetic rats
were deprived of food overnight (12 h), after which they
were anesthetized with ether and killed by exsanguination
from the abdominal aorta. Blood was centrifuged at
1200 × g at 4°C for 10 min, and the plasma was collected.
The livers of all rats in both groups were removed. Fecal
samples of the rats in each group were obtained at the end of
the experimental period. All samples were frozen at 70°C
until analysis.
Analysis
RBO and soybean oil were analyzed for γ-tocotrienol and
γ-oryzanol by high-performance liquid chromatography
(HPLC) using a method described previously [18]. The
HPLC system consisted of a Hitachi L-2000 pump equipped
with a Hitachi AS-2000 autosampler and a Hitachi L-7455
diode array detector (Hitachi, Ltd., Tokyo, Japan). A C18
normal-phase chromatography column (5 SL-II, 4.6 × 250
mm, 5 mm; Cosmoscil, Nacalai Tesque) was used. The flow
rate was set at 1.0 mL/min, and the wavelength of the
detector was set at 295 nm for the detection of γ-tocotrienol
and γ-oryzanol. The mobile phase was hexane:isopropanol
(99:1, v:v). The percentages of fatty acids in the RBO and
Table 1. Composition of experimental diets1,2
1 C: control group; RBO: rice bran oil group.
2 Modified AIN-93M (American Institute of Nutrition, 1993).
3 Rice bran oil content 0.035 g per gram.
C RBO
(g/kg diet)
Cornstarch 449.5 449.5
Casein 200 200
Sucrose 100 100
Soybean oil 150 —
Rice bran oil — 150
Fiber 50 50
Mineral mix 35 35
Vitamin mix 10 10
L-cystine 3 3
Choline bitartrate 2.5 2.5
γ-oryzanol (g/150 g oil) — 5.253
γ-tocotrienol (g/150 g oil) — 0.9Rice Bran Oil and Type 2 Diabetes
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soybean oil were analyzed by gas chromatography [19]. The
percentages of saturated fatty acid (SFA), monounsaturated
fatty acid (MUFA), and polyunsaturated fatty acid (PUFA)
in the soybean oil were 16%, 25%, and 59%, respectively.
The percentages of SFA, MUFA, and PUFA in RBO were
18%, 42%, and 40%, respectively (Table 2). The plasma
glucose, TG, TC, HDL-C, LDL-C, and NEFA concentrations
were determined spectrophotometrically using a glucose
kit, TG kit, cholesterol kit, LDL-C kit, and NEFA kit,
respectively (Randox, Antrim, United Kingdom). The plasma
insulin concentration was measured by using a rat insulin
enzyme-linked immunosorbent assay kit (Mercodia, Uppsala,
Sweden). TGs and cholesterol from liver samples were
extracted [20] and measured using a TG kit and a cholesterol
kit (Randox, Antrim, United Kingdom). The total fatty acid
composition of plasma and hepatic lipids was quantified
using a one-step direct transesterification procedure carried
out in a 4:1 methanol:hexane solution with acetyl chloride
in all steps, as previously described [21]. The fatty acids
were analyzed by gas chromatography with a G-3000
chromatograph (Hitachi Ltd, Tokyo, Japan) with flame
ionization detection. Separations were performed on a
Stabilwax-DA capillary column (30 m × 0.53 mm i.d.; film
thickness, 0.5 μm; RESTEK). Individual fatty acids in the
plasma and liver were calculated using 17:0 fatty acid as an
internal standard. Identification was based on the retention
time. Individual fatty acid levels were expressed as a
percentage of total fatty acids. Because the amount of the
fecal sample for individual rats in the same group was
insufficient to analyze neutral sterols and bile acids, fecal
samples were pooled in the same group, divided into 5 equal
portions, freeze-dried, and ground. Neutral sterols and bile
acids were extracted and determined [21] using cholesterol
and bile acids kits (Randox, Antrim, United Kingdom).
Intraperitoneal glucose tolerance test (IPGTT)
At week 0 and week 5, diabetic rats were deprived of
food overnight for 12 h and injected intraperitoneally with
glucose (0.5 mg/kg BW). Venous blood samples were then
collected at 0, 15, 30, 60, 90, 120, and 180 min for the
measurement of plasma glucose and insulin. Insulin resis-
tance was estimated by the product of the AUCs for glucose
and insulin as previously used by Cortez et al. [22].
Statistical analysis
Values were expressed as means ± standard deviations
(SDs). Comparisons of data from two groups were con-
ducted by student’s t test by using SAS statistical software
(version 8.2; SAS Institute Inc., Cary, NC). Differences were
considered significant at p<0.05.
Results
Weight gain and food intake
The daily food intake during the experimental period did
not differ between groups, and weight gain was also
unaffected by the diet. No side effects, such as diarrhea or
death, occurred in rats fed the experiment diet, and no rats
died as a result of T2DM being induced by the STZ injec-
tions (Table 3).
Plasma glucose, insulin concentrations, and insulin sensitivity
After 5 weeks of treatment, the plasma glucose and
insulin concentrations of rats did not differ between the
groups (Table 4). AUCs for glucose and insulin are a
measure of insulin sensitivity, and the AUC for glucose did
not differ between groups. The AUC for insulin was signifi-
Table 2. Fatty acid composition of experimental oils1,2
1 Values are means ± SD, n =3 .
2 * means there is significant difference between soybean oil and
rice bran oil (p<0.05).
3 SFA: saturated fatty acid; MUFA: monounsaturated fatty acid;
PUFA: polyunsaturated fatty acid.
Soybean oil Rice bran oil
(percent to total fatty acids)
C14: 0 0.1 ± 0.0 0.4 ± 0.0*
C16: 0 11.4 ± 0.0 17.3 ± 0.5*
C18: 0 3.8 ± 0.2 —
C20: 0 0.3 ± 0.1 0.5 ± 0.1*
C22: 0 0.4 ± 0.0 0.2 ± 0.0*
ΣSFA3 16.0 ± 0.2 18.3 ± 0.3
C16: 1 — 0.1 ± 0.0
C18: 1 24.8 ± 0.5 42.0 ± 0.1*
ΣMUFA3 24.8 ± 0.5 42.1 ± 0.2*
C18: 2 53.0 ± 0.3 38.5 ± 0.2* 
C18: 3 6.2 ± 0.2 1.2 ± 0.2* 
ΣPUFA3 59.2 ± 0.3 40.0 ± 0.2* 
Table 3. Food intake, body weight, weight gain, liver weight,
relative liver weight, epididymal fat weight, relative
epididymal fat weight in diabetic rats after 5-week
experimental diets1,2
1 C: control group; RBO: rice bran oil group.
2 Values are means ± SD, n =8 .
C RBO
Food intake (g/day) 20.0 ± 1.9 19.3 ± 1.8
Weight (g) 471.3 ± 51.2 424.9 ± 32.1
Weight gain (g) 74.3 ± 20.0 63.2 ± 17.8
Liver weight (g) 11.9 ± 1.7 11.83 ± 1.2
Relative liver weight (%) 2.5 ± 0.2 2.7 ± 0.1
Epididymal fat weight (g) 13.1 ± 2.6 10.2 ± 2.0
Relative epididymal fat weight (%) 2.8 ± 0.4 2.4 ± 0.4T.-W. Chou et al.
J. Clin. Biochem. Nutr.
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cantly lower in the RBO group than in the control group
(p<0.05) (Table 4).
Plasma cholesterol concentrations
After 5 weeks of treatment, plasma TC and LDL-C
concentrations did not differ between the two groups. The
HDL-C concentration was higher in the RBO group than in
the control group. The TC/HDL-C ratio was lower in the
RBO group than in the control group (Table 4).
Plasma TG and NEFA concentrations
Plasma TG concentrations did not differ between the
groups. But the plasma NEFA concentration was signifi-
cantly lower in the RBO group than in the control group
after 5 weeks of treatment (Table 4).
Hepatic cholesterol and TG concentrations
The hepatic TG concentration did not differ between
the two groups after 5 weeks of treatment. The hepatic
cholesterol concentration was lower in the RBO group than
in the control group (Table 4).
Fecal neutral sterol and bile acid contents
The fecal neutral sterol and bile acid contents were
significantly higher in the RBO group than in the control
group at the end of week 5 (Table 4).
Plasma and hepatic fatty acid composition
After 5 weeks of treatment, plasma and hepatic fatty acid
compositions were consistent with the composition of the
RBO. Total SFAs and MUFAs in plasma and liver were
higher in the RBO group than in the control group. Total
PUFAs in plasma and liver were lower in the RBO group
than in the control (Tables 5 and 6).
Discussion
Individuals with T2DM have an increased risk of
mortality, primarily because of CVD [2, 3]. An important
risk factor for the development of CVD [4] is dyslipidemia,
and randomized controlled studies have shown that lipid-
lowering treatments reduce the risk of CVD and death [5].
The present study showed that an RBO diet containing
γ-oryzanol and γ-tocotrienol maintained plasma glucose
concentrations; lowered the AUC for insulin, plasma NEFA
concentrations, the TC/HDL-C ratio, and the hepatic
cholesterol concentrations; increased the HDL-C concentra-
tion; and increased the fecal excretion of bile acids and
neutral sterols in diabetic rats fed the RBO diet compared
with rats fed a soybean oil diet that served as control and
contained no γ-tocotrienol or γ-oryzanol. Thus, a diet
containing RBO may improve lipid abnormalities and
Table 4. Plasma and hepatic biomarker in diabetic rats after 5-
week experimental diets1–3
1 C: control group; RBO: rice bran oil group.
2 Values are means ± SD, n =8 .
3 * means there is significant difference between control group and
RBO group (p<0.05).
4 AUCglucose: area under the curve for glucose; AUCinsulin: area under
the curve for insulin.
5 TC: total cholesterol; LDL-C: low-density lipoprotein cholesterol;
HDL-C: high-density lipoprotein cholesterol; NEFA: non-esterified
fatty acid.
C RBO
Glucose (mg/dL) 192.1 ± 24.7 199.7 ± 18.2
Insulin (ug/L) 2.09 ± 0.73 2.29 ± 0.92
AUCglucose4 (mg × min/dL) 49734 ± 9480 49285 ± 6836
AUCinsulin4 (μg × min/L) 290.4 ± 65.0 218.7 ± 65.9*
TC5 (mg/dL) 77.5 ± 12.7 79.6 ± 5.0
LDL-C5 (mg/dL) 18.7 ± 6.5 18.0 ± 5.9
HDL-C5 (mg/dL) 53.7 ± 3.2 61.1 ± 2.9*
TC/HDL-C 1.5 ± 0.3 1.3 ± 0.0*
Triglyceride (mg/dL) 61.0 ± 18.7 59.3 ± 15.3
NEFA (mmol/L) 0.70 ± 0.07 0.58 ± 0.09*
Triglyceride (mg/g liver) 948.1 ± 67.0 929.7 ± 34.7
Cholesterol (mg/g liver) 159.7 ± 28.0 129.3 ± 17.5*
Neutral sterol (mg/g feces) 5.09 ± 0.15 15.03 ± 1.71*
Bile acid (μg/g feces) 0.80 ± 0.02 2.88 ± 0.17*
Table 5. Plasma fatty acid compositions in diabetic rats after 5-
week experimental diets1–3
1 C: control group; RBO: rice bran oil group.
2 Values are means ± SD, n =8 .
3 * means there is significant difference between control group and
RBO group (p<0.05).
4 SFA: saturated fatty acid; MUFA: monounsaturated fatty acid;
PUFA: polyunsaturated fatty acid.
CR B O
(percent to total fatty acids)
C14: 0 — —
C16: 0 22.1 ± 0.6 25.0 ± 1.1*
C18: 0 16.7 ± 2.0 16.8 ± 1.8
ΣSFA4 36.9 ± 0.8 41.1 ± 2.5*
C16: 1 1.1 ± 0.2 1.1 ± 0.2
C18: 1 7.6 ± 1.7 13.4 ± 2.7*
ΣMUFA4 8.4 ± 1.7 14.8 ± 2.7*
C18: 2 20.9 ± 2.7 16.1 ± 2.4*
C18: 3 0.9 ± 0.2 —
C20: 4 28.2 ± 3.2 24.3 ± 7.9 
C22: 6 3.2 ± 0.8 3.3 ± 0.3
ΣPUFA 4 52.5 ± 2.0 43.7 ± 5.8*Rice Bran Oil and Type 2 Diabetes
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reduce the increased atherogenic index in rats with STZ/
nicotinamide-induced T2DM.
In various animal species, several syndromes resembling
type 2 DM either occur spontaneously or can be induced
experimentally by different procedures [23]. None of these
syndromes is able to reproduce the complexity of human
diabetes. It should be noted that two well-recognized experi-
mental models of type 2 DM without associated obesity
(i.e., partially pancreatectomized rats and rats subjected to a
neonatal administration of streptozotocin) are characterized
by a substantial reduction in beta-cell mass [24–26] that is
considered to occur also in type 2 DM patients [27, 28]. In a
commonly used genetic model of type 2 DM, the Goto-
Kakizaki (GK) rat, beta -cell mass depletion precedes the
onset of metabolic abnormalities [29]. In rats neonatally
administered STZ (n-STZ rats), another remarkable differ-
ence from type 2 DM is the lack of insulin response to
tolbutamide in the presence of glucose [30]. In GK rats, a
stimulatory effect on insulin release from isolated islets has
been shown after incubation with glucose and gliclazide
[31]. In the present study, the experimental models of type 2
DM were modified from Masiello et al. [14]. The method
took advantage of the partial protection exerted by suitable
dosages of nicotinamide against the beta-cytotoxic effect of
STZ to form an experimental diabetic syndrome in adult rats
that appears closer to type 2 DM than other available animal
models. Other advantages of this syndrome include 1) the
facility of the induction of diabetes, 2) the high yield of
mildly diabetic animals, and 3) the stability of metabolic
alterations. This is the reason this animal model was chosen
in this study.
In our study, the RBO diet had higher SFA and MUFA
contents but a lower PUFA content than did the soybean oil
diet. In addition, the RBO diet contained 3.02 mg/g of
α-tocopherol, 35.22 mg/g of γ-oryzanol, and 0.60 mg/g of
γ-tocotrienol. The soybean oil was rich in α-tocopherol
(0.45 mg/g) but did not contain γ-oryzanol or γ-tocotrienol.
A study has shown an influence of RBO and γ-oryzanol
activity on lipid metabolism in animals and humans [32]. In
previous studies, nondiabetic rats were fed for 8 weeks
either a cholesterol-containing or a cholesterol-free diet
to which 10% RBO was added. This diet significantly
decreased plasma TC, LDL-C, and VLDL-C levels [3, 33].
However, we did not observe a significant reduction in
plasma TC, LDL-C, and TG in our study. This difference
likely occurred because of the use of different animal models
and different fat levels in the two studies.
In our study, the proportions of PUFAs and MUFAs in the
plasma and the hepatic fatty acid compositions in the diabetic
rats fed RBO were altered after the intake of RBO, which
agrees with previous studies. Dietary fatty acids were
previously shown to alter plasma and hepatic fatty acid
compositions [34, 35]. In previous studies, it was shown
that a diet with a high MUFA content decreased plasma TG,
cholesterol, and LDL-C levels more than did a high-SFA
diet [36]. However, we did not observe marked changes in
cholesterol, LDL-C, and TG between these two groups. This
comparison showed the effect of plasma and hepatic fatty
acid composition on the blood lipid is multivariate. For
example, the use of different animal models and different
interventional periods will affect outcomes. We believe that
the relationship between the plasma and hepatic fatty acid
compositions and blood lipids needs further study.
In the present study, diabetic rats fed the RBO diet had a
higher HDL-C concentration than did rats in the control
group, which agrees with previous studies. For example,
Sharma and Rukmini [37] showed that rats fed RBO, at the
level of 10% in the diet, for 8 weeks had significantly lower
plasma TC, LDL-C, and VLDL-C concentrations. They also
observed a significant increase in plasma HDL-C. These
findings showed that RBO significantly improve the plasma
lipoprotein pattern in rats. In our study, diabetic rats fed the
RBO diet had a lower TC/HDL-C ratio than did rats in the
control group. Recent data from the Women’s Health Study
indicate that the use of non-HDL-C and the ratio of TC/
HDL-C as predictors of CVD risk are superior to the use of
TC and LDL alone [38]. Thus, we suppose that RBO could
improve the plasma lipoprotein pattern and reduce the risk
of CVD in T2DM rats.
The increased excretion of fecal neutral sterols and bile
acids due to consumption of the RBO diet is explained in
Table 6. Hepatic fatty acid compositions in diabetic rats after 5-
week experimental diets1–3
1 C: control group; RBO: rice bran oil group.
2 Values are means ± SD, n =8 .
3 * means there is significant difference between control group and
RBO group (p<0.05).
4 SFA: saturated fatty acid; MUFA: monounsaturated fatty acid;
PUFA: polyunsaturated fatty acid.
CR B O
(percent to total fatty acids)
C14: 0 0.5 ± 0.0 0.5 ± 0.1
C16: 0 21.2 ± 0.7 24.7 ± 1.6*
C18: 0 14.8 ± 2.4 16.3 ± 2.8
ΣSFA4 36.4 ± 2.8 41.5 ± 3.2*
C16: 1 0.7 ± 0.2 0.8 ± 0.2
C18: 1 13.4 ± 2.4 21.2 ± 3.9*
ΣMUFA4 14.0 ± 3.3 22.0 ± 4.0*
C18: 2 28.4 ± 2.5 18.2 ± 3.0*
C18: 3 1.2 ± 0.2 0.3 ± 0.1*
C20: 4 15.6 ± 2.2 16.8 ± 2.5
C22: 6 4.6 ± 1.3 4.3 ± 1.5
ΣPUFA4 49.6 ± 1.6 36.5 ± 5.0*T.-W. Chou et al.
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part by the reduction in cholesterol reabsorption in the
intestines. This finding agrees with previous studies in
rats, which showed a mechanism of cholesterol absorption
inhibition by phytosterols, the chemical structure of which is
very similar to that of cholesterol. Phytosterols interfere with
cholesterol movement into micelles and reduce cholesterol
absorption in the intestines. In addition, phytosterols in-
crease the excretion of bile acids, which results in a lowering
of plasma and liver cholesterol levels [39]. In this study,
we also found that RBO affected the fecal excretion of
cholesterol and bile acids as well. It significantly increased
the fecal excretion of bile acids and neutral sterols.
In the present study, none of the experimental diets con-
tained cholesterol; thus, the neutral sterol in feces would
have been catabolized mainly from cholesterol synthesized
in vivo. We speculated that the HMG-CoA reductase
activity–lowering effect of γ-tocotrienol in RBO was
probably overshadowed by the effect of γ-oryzanol on
HMG-CoA reductase activity, because γ-oryzanol consump-
tion resulted in a higher excretion of fecal neutral sterols and
bile acids, which resulted in increased cholesterol synthesis
and catabolism in vivo.
Tabata and colleagues have shown that an intravenous
injection of 0.5 to 4 mg/day phytosterol for 5 days resulted
in a significantly increased conversion into bile acid in the
rat [40]. Shefer and colleagues [41] reported in rats that
sitosterol consumption at a level of 2% of the diet for 1 week
increased the activity of cholesterol-7α hydroxylase, an
enzyme that limits the rate of conversion of cholesterol into
bile acids [42]. In our study, the excretion of bile acid and
neutral sterols in feces increased significantly in T2DM
rats fed an RBO diet rich in unsaponifiable compounds
and γ-oryzanol. We surmised that the observed reduction of
cholesterol in the liver may have been due to an increase
in the activity of cholesterol-7α hydroxylase in terms of
maintaining the homeostasis of bile acids.
The most common lipid abnormalities in diabetes are
hypertriglyceridemia and hypercholesterolemia [43]. Hyper-
triglyceridemia is also associated with the metabolic
consequences of hyperinsulinemia, i.e., insulin resistance
[44]. Levine and colleagues [45] used the product of the
AUC for glucose and insulin during the oral glucose
tolerance test to derive an estimate of insulin sensitivity. In
our study, these variables improved in rats with STZ-
induced T2DM fed an RBO diet (p<0.05). In addition, the
rats with T2DM fed an RBO diet had a significantly lower
AUC for insulin. This finding agrees with that of a previous
study in which diabetic rats fed a 15% RBO diet had a
significantly lower fasting insulin/glucose ratio than did
those fed a soybean oil diet [46]. We found for the first time
that diabetic rats fed an RBO diet exhibited a significantly
suppressed hyperinsulinemic response to a high-fat diet. In a
previous study, a diet high in MUFAs was shown to decrease
postprandial plasma glucose and insulin levels [47].
In the present study, we speculated that rats fed the RBO
diet had a suppressed hyperinsulinemic response that may
have resulted from the higher MUFA dietary intake and
lower hepatic TG concentrations than in rats fed the control
diet. The reduction in hepatic TG accumulation is associated
with decreased insulin resistance [48]. Insulin resistance is
associated with an increase in the 3 main sources of TG
for VLDL assembly: NEFA flux from adipose tissue to the
liver, hepatic uptake of VLDL, intermediate-density lipo-
protein, and chylomicron remnants, and de novo lipogenesis
[49]. In T2DM, the ability of insulin to inhibit lipolysis is
impaired and plasma NEFA concentrations are elevated
[50]. Chronically elevated plasma NEFA concentrations
aggravate insulin resistance [51]. However, the exact
mechanism responsible for the suppression of the hyper-
insulinemic response by RBO is not clear and requires
further study. In addition, the results showed the body
weight, weight gain, and epididymal fat weight had a lower
tendency in RBO group than in control group. We observed
that there was no significant differences of food intake
between two groups, thus we speculate this tendency did not
result from the taste problem of RBO but resulted from that
RBO could affect the lipid metabolism via decreasing the
AUC for insulin. When increasing in plasma insulin will
stimulate the transportation of glucose into the adipocytes,
as well as stimulate the synthesis of fat. In our study, we
found that AUC for insulin decreasing significantly in RBO
group and could lead to the reduction of lipogenesis.
However, we think a longer term study is needed to clarify
the mechanism.
In conclusion, consumption of the RBO diet resulted in a
significant reduction in the AUC for insulin, the plasma
NEFA concentration, hepatic cholesterol, and the TC/HDL-
C ratio and an increase in plasma HDL-C and neutral sterol
and bile acid excretion. We speculate that RBO improves
insulin resistance and lipid metabolism in rats with T2DM.
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